Amneal Pharmaceuticals Stock News

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2022 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Chirag Patel - Co-Founder, Co-Chief Executive Officer Chintu Patel - Co-Foun

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - Co-Founde

Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Tony DiMeo – Head-Investor Relations Chirag Patel – President and Co-Chief Ex

Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018.

Amneal Pharmaceuticals and Kashiv Biosciences have announced that their RELEUKO (filgrastim-ayow) biosimilar recently received FDA approval, making it the third filgrastim biosimilar approved…

Amneal Pharmaceuticals <> stock declined following its mixed Q4 results and and non-GAAP EPS guidance below estimates. Q4 revenue rose +5.27% Y/Y to $536.9M. The increase was…

Amneal Pharmaceuticals Inc (NYSE: AMRX ) reports Q4 revenue of $537 million , an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion. Adjusted EPS was $0.18, below the consensus of $0.20, and better than $0.14 posted a year ago. Adjusted EBITDA increased 18% to … Full story available on Benzinga.com